Women’s Health Today—April 1, 2026

This biweekly Women’s Health video recap highlights regulatory progress, mid-stage clinical momentum, cross-border partnering, real-world risk evidence, biosimilar advances, and expanding care access across menopause, oncology, and broader women’s health services.

Dive deeper

In Today’s Newsletter

💊 Pfizer reports atirmociclib Phase 2 topline in metastatic breast cancer [1] [US • 17 Mar 2026]

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-topline-phase-2-results-next Context: FOURLIGHT-1 studied atirmociclib plus fulvestrant versus fulvestrant or everolimus plus exemestane in HR-positive, HER2-negative advanced or metastatic breast cancer after prior CDK4/6 inhibitor treatment.
Key point: Pfizer said the primary endpoint was met, with investigator-assessed PFS improvement, HR 0.60, and a manageable safety profile; discontinuation due to treatment-emergent adverse events was 6.4%.
Implication: May influence prescriber choice and payer reviews pending full data.

❤️ Premature menopause is linked to higher lifetime coronary heart disease risk [2] [US • 19 Mar 2026]

https://www.health.com/menopause-before-age-40-may-raise-your-lifetime-risk-of-heart-disease-11927593
Context: The Health report cites a JAMA Cardiology analysis of just over 10,000 postmenopausal US women from six long-running studies, focused on natural, not surgical, menopause.
Key point: Women with menopause before age 40 had roughly 40% higher lifetime coronary heart disease risk versus women without premature menopause, after adjustment for major risk factors.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧬 Novartis buys into mutant-selective PI3Kα in HR+/HER2- breast cancer [3] [20 Mar 2026]

https://www.novartis.com/news/media-releases/novartis-agrees-acquire-pan-mutant-selective-pi3ka-inhibitor-strengthening-its-breast-cancer-pipeline
Context: The deal centers on SNV4818, an oral pan-mutant-selective PI3Kα inhibitor in Phase 1/2, acquired through Pikavation Therapeutics, a Synnovation subsidiary.
Key point: Novartis agreed to pay USD 2 billion upfront and up to USD 1 billion in milestones to add a program designed to target mutant PI3Kα while sparing wild-type PI3Kα.
Implication: Signals pipeline investment and modality expansion.

🧑‍💼 Autoimmune disease survey flags workplace and insurance strain for women [4] [US • 17 Mar 2026]

https://www.businesswire.com/news/home/20260317810017/en/New-Survey-Finds-70-of-Working-Women-with-Autoimmune-Disease-Say-Their-Career-Potential-Has-Suffered
Context: WellTheory and the Autoimmune Association surveyed 250 US working women with autoimmune disease; fieldwork ran 11–18 Feb 2026.
Key point: The survey found 70% said their condition had limited career potential, 68% reported negative work effects, and two-thirds said they stayed in a job because they needed health insurance.
Implication: Could inform employer benefit design and chronic-care support decisions.

🤝 Richter and Fuji Pharma expand women’s health co-development [5] [24 Mar 2026]

https://www.gedeonrichter.com/en/news/260324
Context: The agreement follows a broader strategic collaboration announced on 3 Feb 2026 and includes Richter early-stage projects, the Celmatix portfolio, and the FMC2 project of FimmCyte AG.
Key point: Fuji will help fund R&D and gains rights to develop, manufacture, and commercialize covered candidates in Japan, ASEAN countries, and South Korea.
Implication: Signals pipeline investment and modality expansion.

🌿 European Commission approves Richter’s FYLREVY for postmenopausal HRT [6] [EU • 27 Mar 2026]

https://www.gedeonrichter.com/en/news/260327
Context: FYLREVY, estetrol, was approved after a prior positive CHMP opinion and is applicable across the European Economic Area for postmenopausal oestrogen deficiency symptoms in specified populations.
Key point: Richter said the EC approved FYLREVY as hormone replacement therapy and plans launch from the second half of 2026.
Implication: May influence prescriber choice and payer reviews pending launch and market access decisions.

🧪 Teva gains biosimilar traction in denosumab and omalizumab [7] [US/EU • 30 Mar 2026]

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Gains-Biosimilar-Momentum-with-U-S–FDA-Approval-of-PONLIMSI-denosumab-adet-and-Dual-Filing-Acceptance-for-Biosimilar-Candidate-to-Xolair-omalizumab/default.aspx
Context: Teva announced FDA approval of PONLIMSI, a biosimilar to Prolia, and acceptance for review of its proposed omalizumab biosimilar by both FDA and EMA.
Key point: PONLIMSI is now FDA-approved across all indications of the reference product, while the omalizumab candidate moved into parallel US and EU review.
Implication: Introduces competition that may affect pricing and formulary access.

📱 Health-E Commerce and Wisp extend telehealth into migraine and hormonal acne [8] [US • 26 Mar 2026]

https://www.prnewswire.com/news-releases/health-e-commerce-expands-telehealth-collaboration-with-wisp-to-include-migraine-relief-and-hormonal-acne-treatment-now-available-on-fsa-store-and-hsa-store-302725037.html
Context: Wisp services are available in all 50 states, consultations are online with licensed clinicians, and the company says it serves more than 1.8 million patients nationwide.
Key point: Health-E Commerce expanded its Wisp collaboration so FSA Store and HSA Store users can access telehealth services for migraine relief and hormonal acne, alongside existing menopause, fertility, and sexual health offerings.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

Why It Matters

HR+/HER2- breast cancer remained the densest news cluster this week, spanning Pfizer’s CDK4 program [1] and Novartis’s PI3Kα dealmaking [3].
Menopause care moved on both evidence and product fronts, with cardiovascular risk framing from premature menopause research [2] and a new EU HRT approval for FYLREVY [6].
Women’s health infrastructure broadened beyond therapeutics, through cross-border R&D partnering [5] and consumer-facing telehealth distribution [8].
Access and affordability stayed central, whether through employer-linked insurance dependence in autoimmune disease [4] or biosimilar competition in bone health and allergy/immunology markets [7].
Several items remain early or source-limited, so full clinical, regulatory, and commercial impact will depend on later data disclosures and launches [1][3][5][8].

📚 View the full Women’s health archive on our research hub page.

🎯 Catch up on the Top Women’s Health news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

FAQ

What did Pfizer report for atirmociclib in FOURLIGHT-1?

Pfizer said atirmociclib plus fulvestrant improved investigator-assessed progression-free survival versus comparator therapy in second-line HR+/HER2- advanced or metastatic breast cancer. Overall survival was not mature at analysis.[1]

Why does the premature menopause study matter for cardiology and menopause care?

The reported finding is that natural menopause before age 40 was associated with higher lifetime coronary heart disease risk in both Black and white women. It supports using reproductive history in cardiovascular risk assessment.[2]

What is Novartis acquiring from Synnovation Therapeutics?

Novartis is acquiring a subsidiary holding SNV4818 and related pan-mutant-selective PI3Kα programs. SNV4818 is in Phase 1/2 and is positioned for HR+/HER2- breast cancer and potentially other solid tumors.[3]

What changed for Richter in women’s health this week?

Richter announced a co-development agreement with Fuji Pharma covering early-stage women’s health candidates and separate EC approval for FYLREVY, an estetrol-based HRT for postmenopausal symptoms in the EEA.[5][6]

What is Teva’s latest biosimilar progress?

Teva received FDA approval for PONLIMSI, its denosumab biosimilar to Prolia, and said its proposed omalizumab biosimilar was accepted for review by both FDA and EMA.[7]

How is Wisp’s collaboration with Health-E Commerce expanding?

The collaboration now includes telehealth access for migraine and hormonal acne through FSA Store and HSA Store, adding to prior offerings in menopause support, fertility care, and women’s sexual health.[8]

Entities / Keywords

Atirmociclib, Pfizer, FOURLIGHT-1, CDK4 inhibitor, CDK4/6 inhibitor, fulvestrant, everolimus, exemestane, HR-positive breast cancer, HER2-negative breast cancer, metastatic breast cancer
Premature menopause, natural premature menopause, coronary heart disease, JAMA Cardiology, Northwestern University, women’s heart health
Novartis, Synnovation Therapeutics, Pikavation Therapeutics, SNV4818, PI3Kα inhibitor, pan-mutant-selective PI3Kα, PIK3CA mutation, HR+/HER2- breast cancer
WellTheory, Autoimmune Association, autoimmune disease, women in the workplace, employer-based insurance, workplace accommodations
Gedeon Richter, Fuji Pharma, Celmatix, FimmCyte, FMC2, women’s health R&D, Japan, ASEAN, South Korea
FYLREVY, estetrol, DONESTA, hormone replacement therapy, HRT, menopause, European Commission, EMA, CHMP
Teva, PONLIMSI, denosumab-adet, Prolia, omalizumab, Xolair, biosimilar, FDA, EMA
Health-E Commerce, FSA Store, HSA Store, Wisp, telehealth, migraine, hormonal acne, menopause support